European Journal of Biomedical and Pharmaceutical Sciences

COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION (POOLED ANALYSIS FROM PARADIGM AND DAPA HF TRIALS)

*Mohammed Habib, MD, PhD

ABSTRACT

Bakground: The Dapagliflozin was associated with a reduction in cardiovascular mortality, all-cause mortality, and hospitalizations in patients with heart failure and reduced ejection fraction. Objective: To estimate the cost-effectiveness of Dapagliflozin in Gaza. Design, Setting, and Participants: Quality of life was based on trial EQ-5D scores. Hospital costs combined Medicare and private insurance reimbursement rates; medication costs included the wholesale acquisition cost for sacubitril/valsartan and Dapagliflozin. were performed on key inputs including: hospital costs, mortality benefit, hazard ratio for hospitalization reduction, drug costs, and quality-of-life estimates. Main Outcomes and Measures: Hospitalizations, quality-adjusted life-years (QALYs), costs, and incremental costs per QALY gained. Results: In DAPA HF trial: in patient with DM, the strategy of using dapagliflozin has an of $ 17287 per QALY gained and in patient without DM, the strategy of using dapagliflozin has an of $ 45192 per QALY gained. Indirect comparison between patients with dapagliflozin but without DM the strategy of using sacubitril/ valsartan has an ICER of $ 66000 per QALY gained and in patient with DM, ICER of 94 000 $ per QALY gained. Conclusions: For eligible patients with HF and reduced ejection fraction, Dapagliflozin was cost effective than the sacubitril/valsartan in Gaza.

Keywords: .